Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda
Abstract Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-04732-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234981561303040 |
|---|---|
| author | Jean Claude Mugisha Etienne Kayigi Noel Gahamanyi Henri Desire Uwayo Fidele Umwanankabandi Pierre Gashema Edison Rwagasore David Turatsinze Menelas Nkeshimana Misbah Gashegu Edward Ntagwabira Lyndah Makayoto Jean Claude Semuto Ngabonziza Isabelle Mukagatare Albert Tuyishime Nadine Rujeni Leon Mutesa Eric Seruyange Sanctus Musafiri Theogene Twagirumugabe Jean de Dieu Harelimana Claude Mambo Muvunyi |
| author_facet | Jean Claude Mugisha Etienne Kayigi Noel Gahamanyi Henri Desire Uwayo Fidele Umwanankabandi Pierre Gashema Edison Rwagasore David Turatsinze Menelas Nkeshimana Misbah Gashegu Edward Ntagwabira Lyndah Makayoto Jean Claude Semuto Ngabonziza Isabelle Mukagatare Albert Tuyishime Nadine Rujeni Leon Mutesa Eric Seruyange Sanctus Musafiri Theogene Twagirumugabe Jean de Dieu Harelimana Claude Mambo Muvunyi |
| author_sort | Jean Claude Mugisha |
| collection | DOAJ |
| description | Abstract Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures that can be used to monitor MVD progression in Marburg virus (MARV)-infected patients. We performed a retrospective analysis of biochemical and hematological data collected from 51 MARV-infected patients in Rwanda. The study subjects were classified according to the day of discharge: early (< 5 days), middle (5–10 days) and late recovery (> 10 days). Our data revealed that Aspartate transaminase (AST), Alanine transaminase (ALT)), and creatinine were significantly lower in MVD-recovered subjects as compared to newly admitted patients (p < 0.0001 each). Lymphocytes and platelets were increased in MVD-recovered subjects (p < 0.0001 and p < 0.001, respectively). ALT levels discriminated between middle, late recovered individuals, and MVD patients (AUC: 0.86, 0.90, 0.94, respectively). AST also showed strong discriminatory power for middle, late recovery, and MVD patients (AUC: 0.81, 0.95, 0.94, respectively). Similarly platelets differentiated the middle, late MVD-recovered groups and MVD patients (AUC: 0.79,0.61, 0.90, respectively). Creatinine and lymphocytes were also suggested as potential biomarkers for MVD development. These findings provide novel insights into biological factors crucial for MVD management. Although all investigated biomarkers can be used to monitor MVD patients, our analyses highlight key biosignatures that can guide clinicians to track MVD progression and enable real-time decisions. |
| format | Article |
| id | doaj-art-2967e11bc8f24dd6b8c2947c4259972b |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-2967e11bc8f24dd6b8c2947c4259972b2025-08-20T04:02:56ZengNature PortfolioScientific Reports2045-23222025-07-011511910.1038/s41598-025-04732-8Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in RwandaJean Claude Mugisha0Etienne Kayigi1Noel Gahamanyi2Henri Desire Uwayo3Fidele Umwanankabandi4Pierre Gashema5Edison Rwagasore6David Turatsinze7Menelas Nkeshimana8Misbah Gashegu9Edward Ntagwabira10Lyndah Makayoto11Jean Claude Semuto Ngabonziza12Isabelle Mukagatare13Albert Tuyishime14Nadine Rujeni15Leon Mutesa16Eric Seruyange17Sanctus Musafiri18Theogene Twagirumugabe19Jean de Dieu Harelimana20Claude Mambo Muvunyi21College of Medicine and Health Sciences, University of RwandaRwanda Biomedical CenterRwanda Biomedical CenterRwanda Biomedical CenterRwanda Biomedical CenterRwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of HealthRwanda Biomedical CenterButare University Teaching HospitalMinistry of HealthRwanda Biomedical CenterRwanda Biomedical CenterWorld Health OrganizationRwanda Biomedical CenterRwanda Biomedical CenterRwanda Biomedical CenterWorld Health OrganizationCollege of Medicine and Health Sciences, University of RwandaRwanda Military HospitalCollege of Medicine and Health Sciences, University of RwandaButare University Teaching HospitalWorld Health OrganizationRwanda Biomedical CenterAbstract Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures that can be used to monitor MVD progression in Marburg virus (MARV)-infected patients. We performed a retrospective analysis of biochemical and hematological data collected from 51 MARV-infected patients in Rwanda. The study subjects were classified according to the day of discharge: early (< 5 days), middle (5–10 days) and late recovery (> 10 days). Our data revealed that Aspartate transaminase (AST), Alanine transaminase (ALT)), and creatinine were significantly lower in MVD-recovered subjects as compared to newly admitted patients (p < 0.0001 each). Lymphocytes and platelets were increased in MVD-recovered subjects (p < 0.0001 and p < 0.001, respectively). ALT levels discriminated between middle, late recovered individuals, and MVD patients (AUC: 0.86, 0.90, 0.94, respectively). AST also showed strong discriminatory power for middle, late recovery, and MVD patients (AUC: 0.81, 0.95, 0.94, respectively). Similarly platelets differentiated the middle, late MVD-recovered groups and MVD patients (AUC: 0.79,0.61, 0.90, respectively). Creatinine and lymphocytes were also suggested as potential biomarkers for MVD development. These findings provide novel insights into biological factors crucial for MVD management. Although all investigated biomarkers can be used to monitor MVD patients, our analyses highlight key biosignatures that can guide clinicians to track MVD progression and enable real-time decisions.https://doi.org/10.1038/s41598-025-04732-8Marburg virusKineticsBiomarkersDisease progressionRwanda |
| spellingShingle | Jean Claude Mugisha Etienne Kayigi Noel Gahamanyi Henri Desire Uwayo Fidele Umwanankabandi Pierre Gashema Edison Rwagasore David Turatsinze Menelas Nkeshimana Misbah Gashegu Edward Ntagwabira Lyndah Makayoto Jean Claude Semuto Ngabonziza Isabelle Mukagatare Albert Tuyishime Nadine Rujeni Leon Mutesa Eric Seruyange Sanctus Musafiri Theogene Twagirumugabe Jean de Dieu Harelimana Claude Mambo Muvunyi Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda Scientific Reports Marburg virus Kinetics Biomarkers Disease progression Rwanda |
| title | Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda |
| title_full | Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda |
| title_fullStr | Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda |
| title_full_unstemmed | Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda |
| title_short | Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda |
| title_sort | kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in marburg virus infected patients in rwanda |
| topic | Marburg virus Kinetics Biomarkers Disease progression Rwanda |
| url | https://doi.org/10.1038/s41598-025-04732-8 |
| work_keys_str_mv | AT jeanclaudemugisha kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT etiennekayigi kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT noelgahamanyi kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT henridesireuwayo kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT fideleumwanankabandi kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT pierregashema kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT edisonrwagasore kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT davidturatsinze kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT menelasnkeshimana kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT misbahgashegu kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT edwardntagwabira kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT lyndahmakayoto kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT jeanclaudesemutongabonziza kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT isabellemukagatare kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT alberttuyishime kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT nadinerujeni kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT leonmutesa kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT ericseruyange kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT sanctusmusafiri kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT theogenetwagirumugabe kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT jeandedieuharelimana kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda AT claudemambomuvunyi kineticsofhematologicalandbiochemicalbiomarkersarekeytoolsformonitoringdiseaseprogressioninmarburgvirusinfectedpatientsinrwanda |